Personnaz Jean, Piccolo Enzo, Dortignac Alizée, Iacovoni Jason S, Mariette Jérôme, Rocher Vincent, Polizzi Arnaud, Batut Aurélie, Deleruyelle Simon, Bourdens Lucas, Delos Océane, Combes-Soia Lucie, Paccoud Romain, Moreau Elsa, Martins Frédéric, Clouaire Thomas, Benhamed Fadila, Montagner Alexandra, Wahli Walter, Schwabe Robert F, Yart Armelle, Castan-Laurell Isabelle, Bertrand-Michel Justine, Burlet-Schiltz Odile, Postic Catherine, Denechaud Pierre-Damien, Moro Cédric, Legube Gaelle, Lee Chih-Hao, Guillou Hervé, Valet Philippe, Dray Cédric, Pradère Jean-Philippe
Institut RESTORE, UMR 1301, Institut National de la Santé et de la Recherche Médicale (INSERM), CNRS-Université Paul Sabatier, Université de Toulouse, Toulouse, France.
Institut des Maladies Métaboliques et Cardiovasculaires, UMR 1297/I2MC, Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Toulouse, Toulouse, France.
Sci Adv. 2022 Mar 25;8(12):eabg9055. doi: 10.1126/sciadv.abg9055.
Dysregulations of lipid metabolism in the liver may trigger steatosis progression, leading to potentially severe clinical consequences such as nonalcoholic fatty liver diseases (NAFLDs). Molecular mechanisms underlying liver lipogenesis are very complex and fine-tuned by chromatin dynamics and multiple key transcription factors. Here, we demonstrate that the nuclear factor HMGB1 acts as a strong repressor of liver lipogenesis. Mice with liver-specific deficiency display exacerbated liver steatosis, while -overexpressing mice exhibited a protection from fatty liver progression when subjected to nutritional stress. Global transcriptome and functional analysis revealed that the deletion of gene enhances LXRα and PPARγ activity. HMGB1 repression is not mediated through nucleosome landscape reorganization but rather via a preferential DNA occupation in a region carrying genes regulated by LXRα and PPARγ. Together, these findings suggest that hepatocellular HMGB1 protects from liver steatosis development. HMGB1 may constitute a new attractive option to therapeutically target the LXRα-PPARγ axis during NAFLD.
肝脏中脂质代谢的失调可能会引发脂肪变性的进展,导致潜在的严重临床后果,如非酒精性脂肪性肝病(NAFLD)。肝脏脂肪生成的分子机制非常复杂,并受到染色质动态变化和多种关键转录因子的精细调节。在这里,我们证明核因子HMGB1作为肝脏脂肪生成的强力抑制剂。肝脏特异性缺失的小鼠表现出加剧的肝脏脂肪变性,而过度表达的小鼠在受到营养应激时则表现出对脂肪肝进展的保护作用。全基因组转录组和功能分析表明,基因的缺失增强了LXRα和PPARγ的活性。HMGB1的抑制作用不是通过核小体景观的重组介导的,而是通过在携带受LXRα和PPARγ调节基因的区域中优先占据DNA来实现的。总之,这些发现表明肝细胞HMGB1可防止肝脏脂肪变性的发展。在NAFLD期间,HMGB1可能构成治疗靶向LXRα-PPARγ轴的一个新的有吸引力的选择。